American Society of Hematology

Figure 3.

$Clinical parameters of MDS patients with the E592K variant of SF3B1. Compared with cases with exon 14-16 mutations, patients with E592K have (A) higher fractions of MDS-SLD/MLD, MDS-EB, and AML, (B) higher IPSS-M, (C) lower platelets, (D) nearly-absent RS, and (E) lower overall survival which is retained in (F) lower IPSS-M score groups. Outcomes are similarly poor for E592K and exon 14-16 patients in (G) higher IPSS-M score groups.$

Clinical parameters of MDS patients with the E592K variant of SF3B1. Compared with cases with exon 14-16 mutations, patients with E592K have (A) higher fractions of MDS-SLD/MLD, MDS-EB, and AML, (B) higher IPSS-M, (C) lower platelets, (D) nearly-absent RS, and (E) lower overall survival which is retained in (F) lower IPSS-M score groups. Outcomes are similarly poor for E592K and exon 14-16 patients in (G) higher IPSS-M score groups.

This Feature Is Available To Subscribers Only